

Acute Kidney Injury**National Clinical Guideline Centre****Minutes****5th Guideline Development Group Meeting**

Date and Time: *20th January 2012, 10:30 – 16:00*

Place: *NCGC Boardroom, 180 Great Portland Street, London*

GDG Present:

Mark Thomas (Chair) (MT)	Fiona Loud (FL)
Annette Davies (AD)	David Milford (DM)
Anne Dawnay (ADw)	Marlies Ostermann (MO)
Mark Devonald (MD)	Nicholas Palmer (NP)
Coral Hulse (CH)	Sue Shaw (SS)
Chris Laing (CL)	
Andrew Lewington (AL)	

Apologies: Sarah Dunsdon (SD)

NCGC Present: Joanna Ashe (JA) (present for item 7 only)
Caroline Blaine (CB)
Saoussen Ftouh (SF)
Ralph Hughes (RH)
Sue Latchem (SL)
Izaba Younis (IY)

In attendance:

NICE Staff: None present

Expert Advisor: Dr Mark Downes (MDw)

Minutes

- 1. Introductions and apologies.** MT welcomed everyone to the meeting and introduced Dr Mark Downes an expert advisor on radiology. Apologies were received from SD. MO declared a non personal pecuniary interest: she received an honorarium from Biparto for giving a talk. She donated the money to the ICU research fund at St Thomas' hospital.

There were no changes to any of the other GDG members' and NCGC staff's DOIs since the last meeting. No actions were taken following these declarations and none of the GDG members withdrew during discussion.

The minutes of GDG4 were agreed as an accurate reflection of the meeting.

2. **Clinical evidence on prevention of contrast-induced AKI:** IY and CB presented the results of the remaining comparisons of this review.
3. **Summary of evidence and draft recommendations on prevention of CI-AKI** CB presented a summary of all the clinical evidence reviewed for this clinical question. The GDG discussed the evidence and drafted possible recommendations for clinical practice. These will be revisited once the results of the health economics model are available. They also identified areas where further research is needed and drafted research recommendations.
4. **Update on the CI-AKI health economics model-** RH informed GDG that the health economics plan had been signed off by NICE subject to minor changes. He then presented the updated CI-AKI model for discussion with the GDG. Several changes were suggested regarding the stages of CKD which RH will include in the final model.
5. **Clinical evidence on urinalysis:** SF presented the results of the clinical review on the use of dipsticks in the detection of the causes of AKI. No clinical studies were found. RH presented health economics considerations. The GDG discussed the results and drafted a recommendation.
6. **Protocols for upcoming reviews:** A group discussion was held to prioritise the clinical questions and refine the protocols for upcoming reviews on prevention of deterioration
7. **Any other business:** MT closed the meeting and thanked everyone for attending.

Date, time and venue of the next meeting

Tuesday 6th of March 2012, NCGC Boardroom, 180 Great Portland Street, London